| [1] |
Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China [J]. J Am Soc Nephrol, 2016, 27(12): 3739-3746.
|
| [2] |
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
|
| [3] |
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy [J]. N Engl J Med, 2014, 371(24): 2277-2287.
|
| [4] |
Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/exostosin 2-associated membranous nephropathy [J]. J Am Soc Nephrol, 2019, 30(6): 1123-1136.
|
| [5] |
Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy [J]. Kidney Int, 2020, 97(1): 163-174.
|
| [6] |
Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(7): 1666-1681.
|
| [7] |
Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients [J]. Kidney Int, 2020, 98(5): 1253-1264.
|
| [8] |
Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis [J]. Kidney Int, 2021, 100(1): 171-181.
|
| [9] |
Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy [J]. J Am Soc Nephrol, 2021, 32(5): 1249-1261.
|
| [10] |
Caza TN, Hassen SI, Kenan DJ, et al. Transforming growth factor beta receptor 3 (TGFBR3)-associated membranous nephropathy [J]. Kidney360, 2021, 2(8): 1275-1286.
|
| [11] |
Le Quintrec M, Teisseyre M, Bec N, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy [J]. Kidney Int, 2021, 100(6): 1240-1249.
|
| [12] |
Hofstra JM, Wetzels JF. Anti-PLA2R antibodies in membranous nephropathy: ready for routine clinical practice? [J]. Neth J Med, 2012, 70(3): 109-113.
|
| [13] |
杨晶，邱晓楠，柳彩侠. 血清抗PLA2R抗体和sST2在特发性膜性肾病中的水平及临床意义[J]. 检验医学与临床，2022, 19(6): 758-761, 765.
|
| [14] |
Hu S, Wang D, Gou WJ, et al. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis [J]. J Nephrol, 2014, 27(2): 111-116.
|
| [15] |
Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy [J]. J Am Soc Nephrol, 2014, 25(6): 1357-1366.
|
| [16] |
Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy [J]. J Am Soc Nephrol, 2018, 29(2): 401-408.
|
| [17] |
Reinhard L, Zahner G, Menzel S, et al. Clinical relevance of domain-specific phospholipase A2 receptor 1 antibody levels in patients with membranous nephropathy [J]. J Am Soc Nephrol, 2020, 31(1): 197-207.
|
| [18] |
Beck LH Jr, Salant DJ. Refining our understanding of the PLA2R-antibody response in primary membranous nephropathy: looking forward, looking back [J]. J Am Soc Nephrol, 2020, 31(1): 8-11.
|
| [19] |
Iwakura T, Ohashi N, Kato A, et al. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy [J]. PLoS One, 2015, 10(9): e0138841.
|
| [20] |
Lwezaula BF, Ameh OI, Ekrikpo UE, et al. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans [J]. BMC Nephrol, 2021, 22(1): 15.
|
| [21] |
Hoxha E, Beck LH Jr, Wiech T, et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy [J]. J Am Soc Nephrol, 2017, 28(2): 520-531.
|
| [22] |
Wang J, Cui Z, Lu J, et al. Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy [J]. Clin J Am Soc Nephrol, 2017, 12(10): 1642-1651.
|
| [23] |
Zhang C, Zhang M, Chen D, et al. Features of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in malignancy-associated membranous nephropathy [J]. J Clin Pathol, 2019, 72(10): 705-711.
|
| [24] |
Nakamura R, Nakamoto C, Obama H, et al. Structure-function analysis of Nel, a thrombospondin-1-like glycoprotein involved in neural development and functions [J]. J Biol Chem, 2012, 287(5): 3282-3291.
|
| [25] |
Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy [J]. Kidney Int, 2021, 99(4): 967-976.
|
| [26] |
Wang G, Sun L, Dong H, et al. Neural epidermal growth factor-like 1 protein-positive membranous nephropathy in Chinese patients [J]. Clin J Am Soc Nephrol, 2021, 16(5): 727-735.
|
| [27] |
Kudose S, Santoriello D, Debiec H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy [J]. Kidney Int, 2021, 99(1): 247-255.
|
| [28] |
Münch J, Krüger BM, Weimann A, et al. Posttransplant nephrotic syndrome resulting from NELL1-positive membranous nephropathy [J]. Am J Transplant, 2021, 21(9): 3175-3179.
|
| [29] |
Kudose S, Sekulic M, Mehring CJ, et al. NELL1-associated membranous glomerulopathy after hematopoietic stem cell transplantation [J]. Kidney Int Rep, 2021, 6(7): 1992-1995.
|
| [30] |
Spain RI, Andeen NK, Gibson PC, et al. Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy [J]. Kidney Int, 2021, 100(6): 1208-1213.
|
| [31] |
Sano K, Tanihara H, Heimark RL, et al. Protocadherins: a large family of cadherin-related molecules in central nervous system [J]. EMBO J, 1993, 12(6): 2249-2256.
|
| [32] |
Masuda T, Taniguchi M. Contribution of semaphorins to the formation of the peripheral nervous system in higher vertebrates [J]. Cell Adh Migr, 2016, 10(6): 593-603.
|
| [33] |
Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome [J]. Science, 2017, 357 (6352): eaan2507.
|
| [34] |
Ravindran A, Madden B, Charlesworth MC, et al. Proteomic analysis of complement proteins in membranous nephropathy [J]. Kidney Int Rep, 2020, 5(5): 618-626.
|
| [35] |
Ravindran A, Casal Moura M, Fervenza FC, et al. In patients with membranous lupus nephritis, exostosin-positivity and exostosin-negativity represent two different phenotypes [J]. J Am Soc Nephrol, 2021, 32(3): 695-706.
|
| [36] |
Saïdi M, Brochériou I, Estève E, et al. The exostosin immunohistochemical status differentiates lupus membranous nephropathy subsets with different outcomes [J]. Kidney Int Rep, 2021, 6(7): 1977-1980.
|
| [37] |
Rinschen MM, Gödel M, Grahammer F, et al. A multi-layered quantitative in vivo expression atlas of the podocyte unravels kidney disease candidate genes [J]. Cell Rep, 2018, 23(8): 2495-2508.
|
| [38] |
Bobart SA, Tehranian S, Sethi S, et al. A target antigen-based approach to the classification of membranous nephropathy [J]. Mayo Clin Proc, 2021, 96(3): 577-591.
|
| [39] |
Nasr SH, Said SM, Valeri AM, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis [J]. Clin J Am Soc Nephrol, 2009, 4(2): 299-308.
|
| [40] |
Iida A, Wada Y, Hayashi J, et al. Membranous nephropathy caused by rheumatoid arthritis [J]. CEN Case Rep, 2019, 8(4): 233-238.
|
| [41] |
Yabuuchi J, Suwabe T, Ueno T, et al. Sjögren syndrome-related membranous glomerulonephritis progressing to membranoproliferative glomerulonephritis [J]. Case Rep Nephrol Dial, 2016, 6(3): 133-142.
|
| [42] |
Wielosz E, Majdan M, Suszek D, et al. Nephrotic syndrome as a clinical manifestation of systemic sclerosis [J]. Rheumatol Int, 2007, 27(11): 1087-1089.
|
| [43] |
Singhania G, Singhania N. Membranous nephropathy associated with profound hypothyroidism [J]. Clin Case Rep, 2019, 8(1): 120-122.
|
| [44] |
Le Quintrec M, Teisseyre M, Bec N, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy [J]. Kidney Int, 2021, 100(6): 1240-1249.
|
| [45] |
Hashimoto Y, Ogata H, Yamasaki R, et al. Chronic inflammatory demyelinating polyneuropathy with concurrent membranous nephropathy: an anti-paranode and podocyte protein antibody study and literature survey [J]. Front Neurol, 2018, 9: 997.
|
| [46] |
Moroni G, Ponticelli C. Secondary membranous nephropathy. A narrative review [J]. Front Med(Lausanne), 2020, 7: 611317.
|